Background: Tumour necrosis factor inhibitor (TNFi) therapy is ineffective for approximately 20% of rheumatoid arthritis (RA) patients and there is currently no way to predict which patients will not benefit. To address this precision medicine question, reliable biomarkers of TNFi response are needed. The role of CD4+ T-cells in the pathogenesis of RA is well established and high dimensional single cell technologies such as mass cytometry (i.e. CyTOF) have revealed a broad diversity of CD4+ T-cells that are expanded in RA and contract with successful treatment (1). However, the precise T-cell subsets and key effector functions driving and perpetuating RA remains to be completely resolved and very few studies have specifically investigated their role in treatment response to TNFi.
Hypothesis: Pre- and early-treatment CD4+ T-cell signatures are correlated with response to TNFi and can be used to better target biologic drugs to the patients with RA most likely to benefit from them.
Methods: PBMCs will be harvested from RA patient (n = 20) upon commencement of TNFi therapy. Samples will be collected at pre-treatment, and 1-hour, followed by trough sampling at 2-weeks, 4-weeks and 6-weeks, with follow-up collection at 3-months. Drug levels will be measured in patient serum at each follow-up visit and disease activity will be recorded using the DAS28.
Immunophenotyping of CD4+ T-cell will be performed using an established CyTOF antibody panel, and visualised using viSNE maps to characterise cell abundance and intracellular signal transduction (2). Regression based techniques will be used to identify the most important cell-types associated with improvement in disease activity during early treatment. Similar techniques will be used to correlate cell-types with trough drug levels.
The outcome of this work has the potential to inform clinical practice and guide the development of new interventions to improve treatment pathways for individuals with RA.
Candidates are expected to hold (or be about to obtain) a minimum upper second class honours degree (or equivalent) in a related area/subject. Candidates with previous laboratory experience, particularly in cell culture and molecular biology, are particularly encouraged to apply.
How To Apply
For information on how to apply for this project, please visit the Faculty of Biology, Medicine and Health Doctoral Academy website (https://www.bmh.manchester.ac.uk/study/research/apply/). Informal enquiries may be made directly to the primary supervisor. On the online application form select PhD Genetics
For international students, we also offer a unique 4 year PhD programme that gives you the opportunity to undertake an accredited Teaching Certificate whilst carrying out an independent research project across a range of biological, medical and health sciences.
Equality, Diversity and Inclusion
Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website https://www.bmh.manchester.ac.uk/study/research/apply/equality-diversity-inclusion/”
For international students we also offer a unique 4 year PhD programme that gives you the opportunity to undertake an accredited Teaching Certificate whilst carrying out an independent research project across a range of biological, medical and health sciences. For more information please visit http://www.internationalphd.manchester.ac.uk